Famygen Life Sci Company Profile
What is the competitive landscape for FAMYGEN LIFE SCI
FAMYGEN LIFE SCI has one approved drug.
There are thirteen US patents protecting FAMYGEN LIFE SCI drugs.
Summary for Famygen Life Sci
| US Patents: | 13 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Famygen Life Sci: | See patent lawsuits for Famygen Life Sci |
Drugs and US Patents for Famygen Life Sci
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 10,278,918 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 10,772,829 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 11,090,261 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Famygen Life Sci | RYZUMVI | phentolamine mesylate | SOLUTION;OPHTHALMIC | 217064-001 | Sep 25, 2023 | RX | Yes | Yes | 9,795,560 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Famygen Life Sci Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102961961 | ⤷ Start Trial |
| Mexico | 2021004708 | ⤷ Start Trial |
| European Patent Office | 4721725 | ⤷ Start Trial |
| China | 113164452 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

